Exploring Synergistic Effects of Combined Chemotherapeutic and Statin Therapy in Triple-Negative Breast Cancer
Foda, M., Salem, M., . Salah, N., El-Khawaga, O. (2024). Exploring Synergistic Effects of Combined Chemotherapeutic and Statin Therapy in Triple-Negative Breast Cancer. EKB Journal Management System, 65(2), 18-22. doi: 10.21608/mjcc.2024.411468
Mohamed Foda; Mohamed L. Salem; Nevin A. . Salah; Omali Y. El-Khawaga. "Exploring Synergistic Effects of Combined Chemotherapeutic and Statin Therapy in Triple-Negative Breast Cancer". EKB Journal Management System, 65, 2, 2024, 18-22. doi: 10.21608/mjcc.2024.411468
Foda, M., Salem, M., . Salah, N., El-Khawaga, O. (2024). 'Exploring Synergistic Effects of Combined Chemotherapeutic and Statin Therapy in Triple-Negative Breast Cancer', EKB Journal Management System, 65(2), pp. 18-22. doi: 10.21608/mjcc.2024.411468
Foda, M., Salem, M., . Salah, N., El-Khawaga, O. Exploring Synergistic Effects of Combined Chemotherapeutic and Statin Therapy in Triple-Negative Breast Cancer. EKB Journal Management System, 2024; 65(2): 18-22. doi: 10.21608/mjcc.2024.411468

Exploring Synergistic Effects of Combined Chemotherapeutic and Statin Therapy in Triple-Negative Breast Cancer

Mansoura Journal of Chemistry
Volume 65, Issue 2, April 2024, Page 18-22  XML PDF (790.11 K)
Document Type: Original Article
DOI: 10.21608/mjcc.2024.411468
View on SCiNiTO View on SCiNiTO
Authors
Mohamed Foda* 1; Mohamed L. Salem2; Nevin A. . Salah3; Omali Y. El-Khawaga3
1Biochemistry division, Chemistry department, Faculty of Science, Mansoura University
2Immunology and Biotechnology Unit, Zoology Department, Faculty of Science, Tanta University, Tanta, Egypt.
3Biochemistry division, Chemistry department, Faculty of Science, Mansoura University.
Abstract
Breast cancer remains one of the most common malignancies affecting women worldwide, with triple-negative breast cancer (TNBC) representing a particularly aggressive and treatment-resistant subtype. TNBC does not express estrogen receptors, progesterone receptors, or HER2, making it ineligible for hormone or HER2-targeted therapies. Consequently, treatment options for TNBC are limited, and the prognosis is often poor. This highlights a critical need for innovative therapeutic strategies that can effectively target this challenging cancer subtype. This study aims to evaluates the synergistic anticancer effects of combining doxorubicin (DOX) and atorvastatin (ATO) on triple-negative breast cancer using the MDA-MB-231 cell line. The combination of DOX and ATO significantly lowered the IC50 value to 10 µM from individual IC50s of 19.9 µM (DOX) and 12.2 µM (ATO), indicating increased efficacy. Analysis using the Combination Index (CI) revealed strong synergism (CI < 1), notably at high (CI = 0.28144 at 50 µM total dose) and low concentrations (CI = 0.47037 at 3.12 µM). Additionally, the Dose Reduction Index (DRI) indicated that effective doses could be significantly reduced (DRI > 6 at Fa = 0.9), suggesting potential for lower side effects. These results advocate for the combined use of DOX and ATO in TNBC treatment and warrant further clinical validation.
Keywords
Triple-negative breast cancer; combination therapy; synergy; Combination Index; Dose Reduction Index
Statistics
Article View: 46
PDF Download: 24